Fundraising Fox
Clasp Therapeutics
Cambridge, US · Founded 2020 · 39 employees on LinkedIn · 7 known investors
Find your way into Clasp Therapeutics
Sign up to see every warm intro you have to Clasp Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Clasp Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.
Investors · 7
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Vivo Capital's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AMar 2024Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Clasp Therapeutics do?
- Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.
- Who are Clasp Therapeutics's investors?
- Clasp Therapeutics's investors include Catalio Capital Management, LP, Cure Ventures, Vivo Capital, BrightEdge, Catalio Capital Management, Novo Holdings, Third Rock Ventures.
- Where is Clasp Therapeutics headquartered?
- Clasp Therapeutics is headquartered in Cambridge, US.